13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001917529
Total reported value
$881.3M
$881.3M
16 檔
90.3%
As reported in its official Q1 2024 Form 13F filing, Atlas Venture Life Science Advisors, LLC's tracked investment portfolio stood at $881.3M with 16 total positions.
During Q1 2024, Atlas Venture Life Science Advisors, LLC's portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | DYN | Dyne Therapeutics Inc | Stock-Other | 21.01% | -3.81% | -18.87% | |
| 2 | KYMR | Kymera Therapeutics Inc | Stock-Other | 19.95% | -11.21% | -8.21% | |
| 3 | IRON | Disc Medicine Inc | Stock-Other | 13.14% | +0.31% | -10.49% | |
| 4 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 9.80% | — | -15.48% | |
| 5 | ✓ | Third Harmonic Bio Inc | Stock-Other | 9.50% | — | — | |
| 6 | KRRO | Korro Bio Inc | Stock-Other | 9.30% | -0.19% | — | |
| 7 | ✓ | Stock-Other | 5.57% | — | — | ||
| 8 | QTTB | Q32 Bio Inc | Stock-Other | 3.29% | +2.23% | — | |
| 9 | GBIOGBX | Generation Bio Co | Stock-Other | 3.11% | — | — | |
| 10 | VIGL | Vigil Neuroscience Inc | Stock-Other | 1.84% | — | — | |
| 11 | REPL | Replimune Group Inc | Stock-Other | 1.58% | — | — | |
| 12 | ✓ | Ikena Oncology Inc | Stock-Other | 0.66% | — | — | |
| 13 | ✓ | Stock-Other | 0.54% | — | — | ||
| 14 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.52% | — | -21.10% | |
| 15 | ✓ | Xilio Therapeutics Inc | Stock-Other | 0.10% | — | -64.02% | |
| 16 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.10% | — | -40.04% |
According to official SEC Form 13F filings, Atlas Venture Life Science Advisors, LLC reported a total U.S. public equity portfolio value of $881.3M across 16 disclosed positions in Q1 2024.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including DYN, KYMR, IRON) accounted for 90.3% of total reported equity market value during Q1 2024.
During Q1 2024, Atlas Venture Life Science Advisors, LLC's top holdings by market value included DYN (21.0%)、KYMR (19.9%)、IRON (13.1%). The largest single position, DYN, represented 21.0% of total portfolio value.
In Q1 2024, Atlas Venture Life Science Advisors, LLC made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.